{
    "clinical_study": {
        "@rank": "35269", 
        "arm_group": [
            {
                "arm_group_label": "Placebo", 
                "arm_group_type": "Placebo Comparator", 
                "description": "Placebo for donepezil hydrochloride capsule administered orally once a day for 16 weeks."
            }, 
            {
                "arm_group_label": "Donepezil", 
                "arm_group_type": "Experimental", 
                "description": "Start at 5 mg donepezil hydrochloride capsule administered orally once a day for 2 weeks, and then receive 10 mgs donepezil hydrochloride capsule orally, once a day for 10 weeks. At some point during the study participant is given placebo for donepezil hydrochloride capsule orally, once a day for 4 weeks."
            }
        ], 
        "brief_summary": {
            "textblock": "This study aims to determine whether the Cogstate testing battery can detect improvements in\n      cognitive function in participants with mild AD. The primary hypothesis is that the standard\n      deviation associated with the change from baseline in average One Card Learning (OCL)\n      repeated measurements after 12 weeks of donepezil treatment is =<0.1"
        }, 
        "brief_title": "Computerized Cognition Testing in Participants With Mild Alzheimer's Disease (AD) Treated With Donepezil (MK-0000-318)", 
        "completion_date": {
            "#text": "February 2016", 
            "@type": "Anticipated"
        }, 
        "condition": "Alzheimer's Disease", 
        "condition_browse": {
            "mesh_term": "Alzheimer Disease"
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Meets  listed criteria for a diagnosis of probable AD\n\n          -  Has a clearly documented history either in medical records or from an informant of\n             cognitive decline over at least 6 months\n\n          -  Has a reliable partner/caregiver who is willing to provide input by participating in\n             assessments\n\n          -  Has results of a physical examination and clinical laboratory tests within normal or\n             clinically acceptable limits\n\n          -  Can communicate with trial staff acceptably, possesses the ability to respond\n             verbally to questions, follow instructions, complete questionnaires, and adhere to\n             visit schedules\n\n          -  Can read at a 9th grade level or equivalent, and has an acceptable history of\n             academic achievement and/or employment\n\n          -  Has a magnetic resonance imaging (MRI) scan that rules out non-AD conditions\n             contributing to cognitive dysfunction\n\n          -  Capably performs the CogState screening battery\n\n          -  Has adequate visual acuity and function\n\n          -  Females are not of childbearing potential\n\n        Exclusion Criteria:\n\n          -  Has ever received acetylcholinesterase inhibitors, memantine, or other symptomatic AD\n             treatment including approved medical foods\n\n          -  Has an uncontrolled, clinically significant medical condition or situation within 3\n             months prior to screening\n\n          -  Has had major surgery within 3 months prior to screening\n\n          -  Has tested positive for human immunodeficiency virus (HIV) or has evidence of an\n             active hepatitis B infection\n\n          -  Has a history of malignancy within the prior 5 years\n\n          -  Is unwilling or ineligible to undergo an MRI scan\n\n          -  Has a history of clinically important structural changes on screening MRI scan\n\n          -  Has a clinically important history of stroke or a diagnosis of vascular dementia\n\n          -  Has evidence of a clinically relevant non-AD neurological disorder\n\n          -  Has a history of head trauma, or serious infectious disease affecting the brain\n             within the prior 3-5 years\n\n          -  Has evidence of a clinically relevant or unstable psychiatric disorder, excepting\n             major depression in remission\n\n          -  Has evidence of a current episode of major depression\n\n          -  Has evidence of Type 4 or Type 5 Suicidal Ideation\n\n          -  Has clinically significant vitamin B12 or folate deficiency in the 6 months prior to\n             screening\n\n          -  Is pregnant, attempting to become pregnant or is nursing children\n\n          -  Has used any investigational drug or participated in any other clinical trial within\n             the prior 30 days\n\n          -  Has a history of alcoholism or drug dependency/abuse within the last 5 years\n\n          -  Has a relative contraindication to donepezil including sick sinus syndrome, third\n             degree heart block, active gastrointestinal (GI) bleeding, Zollinger-Ellison\n             syndrome, uncontrolled peptic ulcer disease, or uncontrolled asthma"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "80 Years", 
            "minimum_age": "55 Years"
        }, 
        "enrollment": {
            "#text": "36", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "February 14, 2014", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT02064920", 
            "org_study_id": "0000-318"
        }, 
        "intervention": [
            {
                "arm_group_label": [
                    "Placebo", 
                    "Donepezil"
                ], 
                "description": "Placebo for donepezil hydrochloride capsule", 
                "intervention_name": "Placebo", 
                "intervention_type": "Drug"
            }, 
            {
                "arm_group_label": "Donepezil", 
                "description": "5 mg donepezil hydrochloride capsule.", 
                "intervention_name": "Donepezil", 
                "intervention_type": "Drug", 
                "other_name": "Aricept"
            }, 
            {
                "arm_group_label": "Donepezil", 
                "description": "10 mg donepezil hydrochloride capsule.", 
                "intervention_name": "Donepezil", 
                "intervention_type": "Drug", 
                "other_name": "Aricept"
            }
        ], 
        "intervention_browse": {
            "mesh_term": "Donepezil"
        }, 
        "is_fda_regulated": "Yes", 
        "is_section_801": "Yes", 
        "lastchanged_date": "June 2, 2014", 
        "location": [
            {
                "facility": {
                    "address": {
                        "city": "Leesburg", 
                        "country": "United States", 
                        "state": "Florida", 
                        "zip": "34748"
                    }, 
                    "name": "Call for Information (Investigational Site 0002)"
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Orlando", 
                        "country": "United States", 
                        "state": "Florida", 
                        "zip": "32806"
                    }, 
                    "name": "Call for Information (Investigational Site 0004)"
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Decatur", 
                        "country": "United States", 
                        "state": "Georgia", 
                        "zip": "30030"
                    }, 
                    "name": "Call for Information (Investigational Site 0005)"
                }, 
                "status": "Recruiting"
            }
        ], 
        "location_countries": {
            "country": "United States"
        }, 
        "number_of_arms": "2", 
        "official_title": "A Clinical Trial to Assess Cognitive Function by Repeated Computerized Testing in Patients With Mild Alzheimer's Disease Treated With Donepezil", 
        "overall_contact": {
            "last_name": "Toll Free Number", 
            "phone": "1-888-577-8839"
        }, 
        "overall_status": "Recruiting", 
        "oversight_info": {
            "authority": "United States: Food and Drug Administration", 
            "has_dmc": "No"
        }, 
        "phase": "Phase 2", 
        "primary_completion_date": {
            "#text": "December 2015", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "measure": "Change from baseline in average OCL measurement over 12 weeks of donepezil treatment", 
            "safety_issue": "No", 
            "time_frame": "Baseline and up to week 16"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT02064920"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": {
            "measure": "Change from week 4 in the proportion of correct responses in the OCL task after 12 weeks of donepezil treatment", 
            "safety_issue": "No", 
            "time_frame": "Week 4 and week 16"
        }, 
        "source": "Merck Sharp & Dohme Corp.", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Merck Sharp & Dohme Corp.", 
                "agency_class": "Industry"
            }
        }, 
        "start_date": "April 2014", 
        "study_design": "Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Diagnostic", 
        "study_type": "Interventional", 
        "verification_date": "June 2014"
    }
}